Compare Consolidated Edison, Inc. (ED) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs McKesson Corporation — how do they compare? Consolidated Edison, Inc. trades at $106.1 (market cap $39.20B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 2.8× Consolidated Edison, Inc.'s market cap, and Consolidated Edison, Inc. pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and McKesson Corporation for 74 Days on average.
| ED | MCK | |
|---|---|---|
Market Cap | $39.20B | $108.46B |
Volume | 2,142,900 | 712,607 |
Sector | Utilities | Health |
52-Week High | $115.46 | $995.69 |
52-Week Low | $95.37 | $725.17 |
Typical Hold Time | 75 Days | 74 Days |
Enterprise Value | $66.05B | $115.00B |
Dividend Yield | 3.31% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $106.10, up 1.39% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The stock's valuation appears reasonable with a P/E of 17.43 and P/S of 2.18, while profitability metrics like a 12.53% net income margin and 8.96% ROE reflect steady utility performance. Recent earnings showed beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains strong cash flow from operations of $4.80 billion in 2025 and continues its dividend aristocrat status with a recent $0.89 dividend declaration.
ED offers stable income appeal with a solid dividend history, supported by regulated utility operations and a $24.8 billion economic impact in New York. However, high debt levels ($24.65 billion long-term) and modest growth prospects pose risks. Analyst sentiment is cautious with 62.96% hold ratings, though the consensus price target of $106.33 aligns with the current price, suggesting limited near-term upside amid economic sensitivity.
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
